Greenwich LifeSciences Inc (GLSI)

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command PremiumJanuary 30, 2026 10:36 AM
PR Newswire (US)

Issued on behalf of Oncolytics Biotech Inc.Equity-Insider.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This regulatory surge signals deep institutional confidence in late-stage platforms capable of commercial conversion. The trend accelerated in January 2026 as Big Pharma intensified its race to acquire assets ahead of a $170 billion patent cliff[2]. Acquirers are now bypassing early-stage speculation to secure validated Phase 3 data and manufacturing infrastructure. This structural shift has directed institutional focus toward Oncolytics Biotech Inc. (NASDAQ: ONCY), AbbVie (NYSE: ABBV), Genmab (NASDAQ: GMAB), ADC Therapeutics (NYSE: ADCT), and Greenwich LifeSciences (NASDAQ: GLSI).  Institutions are prioritizing platforms that can navigate Phase 3 trials, where approximately 50% of candidates still fail[3]. Demonstrated regulatory alignment has become the critical de-risking factor for capital allocation. This environment creates asymmetric upside for organizations that have secured the FDA's flexible approach to BLA submissions and manufacturing validation[4]. The market is now placing a premium on specialized leadership combined with registration-enabling data in commercial-scale disease categories.Oncolytics Biotech Inc. (NASDAQ: ONCY) is building out its leadership team as it moves its cancer treatment pelareorep through late-stage clinical trials targeting several gastrointestinal cancers.The company recently announced two key hires: John McAdory as Executive Vice President of Strategy and Operations, and Yujun Wu as Vice President, Head of Biostatistics. McAdory comes from CG Oncology, where he ran late-stage clinical trials for oncolytic virus therapies (cancer-fighting viruses, similar to pelareorep). Wu joins from Morphic Therapeutic, where he led the statistics department through the company's sale to Eli Lilly, and previously designed multiple Phase 3 oncology trials at Takeda. Both bring the specific expertise needed to execute the complex, multi-country registration trials that determine whether a drug gets FDA approval."John's background running complex, late-stage oncology trials makes him exceptionally well-suited to lead Oncolytics' next phase of execution," said Jared Kelly, CEO of Oncolytics Biotech. "As we progress toward pivotal and registration-enabling studies in anal, pancreatic, and colorectal cancers, his experience will be critical to ensuring disciplined execution, speed, and regulatory alignment."These hires complete a significant management upgrade. Kelly and Chief Business Officer Andrew Aromando both joined from Ambrx Biopharma, which sold to Johnson & Johnson for $2 billion in 2024. The company also added three leading cancer specialists from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center to its gastrointestinal tumor scientific advisory board.The clinical data driving this expansion looks compelling. In colorectal cancer, pelareorep combined with chemotherapy and a vascular endothelial growth factor (VEGF) inhibitor achieved a 33% response rate in patients with KRAS mutations (a genetic marker found in about 40% of colorectal cancers). That's three times better than the 6-11% response rate chemotherapy and a VEGF inhibitor typically achieves in these patients. Response rate measures the percentage of patients whose tumors shrink significantly or disappear entirely.In anal cancer, where treatment options are extremely limited after first-line therapy fails, pelareorep is showing even stronger results. Third-line patients (those who've already failed two prior treatments) saw a 29% response rate with responses lasting around 17 months. That nearly triples the historical benchmarks in a setting where no FDA-approved treatments currently exist.In second-line patients, the 30% response rate more than doubled the 13.8% benchmark for the only FDA-approved immunotherapy available, with responses lasting 15.5 months versus 9.5 months for standard treatment.Oncolytics has also secured FDA agreement on its Phase 3 trial design for pancreatic cancer, clearing the way to launch what would be the only immunotherapy registration trial currently planned for this notoriously difficult-to-treat disease.CONTINUED… Read this and more news for Oncolytics Biotech at: https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/In other recent industry developments and happenings in the market include:AbbVie (NYSE: ABBV) along with partner Genmab (NASDAQ: GMAB) announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study demonstrated improvement in progression-free survival with a hazard ratio of 0.74, along with improvements in complete response rates and duration of response, though overall survival did not reach statistical significance.EPCORE DLBCL-1 is the first Phase 3 study to demonstrate PFS improvement in patients with relapsed/refractory DLBCL treated with a CD3xCD20 T-cell engaging bispecific monotherapy. AbbVie and Genmab will engage global regulatory authorities to discuss next steps while continuing to evaluate epcoritamab across treatment lines and hematologic malignancies.ADC Therapeutics (NYSE: ADCT) reported preliminary full-year 2025 ZYNLONTA net product revenue of approximately $73 million, up from $69.3 million in 2024, with fourth quarter revenue of approximately $22 million representing growth from $16.4 million in the prior-year period. Updated data from the LOTIS-7 Phase 1b trial demonstrated an 89.8% best overall response rate and 77.6% complete response rate across 49 efficacy-evaluable patients with relapsed or refractory diffuse large B-cell lymphoma."During 2025, we delivered meaningful progress across our ZYNLONTA clinical program and extended our expected cash runway at least to 2028," said Ameet Mallik, CEO of ADC Therapeutics. "Assuming positive results, we anticipate potential compendia inclusion for each in the first half of 2027 with LOTIS-5 regulatory approvals to follow."The company expects topline data from its LOTIS-5 Phase 3 confirmatory trial in second-quarter 2026, with cash and cash equivalents of approximately $261 million providing runway at least to 2028. ADC Therapeutics has also completed IND-enabling activities for its PSMA-targeting ADC program.Greenwich LifeSciences (NASDAQ: GLSI) announced the FDA has reviewed and approved the use of the first commercial lot of GP2 vials in its Phase III FLAMINGO-01 trial evaluating GLSI-100, an immunotherapy designed to prevent breast cancer recurrences. Preliminary analysis from the non-HLA-A*02 arm shows approximately 80% reduction in recurrence rate, trending similarly to Phase IIb trial results."With our manufacturing investments in 2023 and 2024, and now the FDA's review and approval to use the first commercial lot of finished GP2 vials in FLAMINGO-01, we have taken major steps to further de-risk the filing of a BLA in the US," said Snehal Patel, CEO of Greenwich LifeSciences. "We plan to start using these new GP2 vials in the coming weeks at all 40 US sites."The 250-patient non-HLA-A*02 arm is now fully enrolled, representing five times more treated patients than the Phase IIb trial. Greenwich LifeSciences holds Fast Track designation for GLSI-100 and plans to submit manufacturing data to regulatory agencies in Europe, the United Kingdom, and Canada.Source: https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT:
Equity Insider
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.aacr.org/blog/2026/01/06/fda-approvals-in-oncology-october-december-2025/ https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html https://www.appliedclinicaltrialsonline.com/view/phase-iii-trial-failures-costly-preventable https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/flexible-requirements-cell-and-gene-therapies-advance-innovationLogo: https://mma.prnewswire.com/media/2840019/Equity_Insider_Logo.jpg





View original content to download multimedia:https://www.prnewswire.com/news-releases/170b-patent-cliff-ignites-biotech-deal-wave-late-stage-platforms-command-premium-302675154.html

Original: $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

If you didn't exit above $20 you were a fool there drug doesn't affect many 

$25

Above )20

GLSI under $20

GLSI 10Q due 4/3

GLSI 10Q due 3/27

GLSI new 52 week hi

FYI the share price has essentially doubled since I posted this.

This post didn’t age so well, did it?
Heheh

$GLSI Added 300 - I add when I can. When Snehal releases the initial Phase 3 data- the tiny float + locked up shares will propel this. P2 was 100% efficacy for HER2 Breast Cancer (record). HIGHEST % Insider Buys in the industry. pic.twitter.com/VOvOGyTnkO— BioPharm_the_Magnificent (@crypto_biotech) October 24, 2023

I like how greenwhich is raising money in stock sales..
Not giving insiders discount to market..

Same way Anavex does it..

You don’t want to be diluted?
Buy more. .. I think it’s fair

Amazing how that pump and dump worked. What a scam.

New to GLSI. WTF happened last night/ this morning? -20% on good news...?

Yes I see brother, wait till BCT*X announces theirs during their presentation tomorrow at 8:30 AM. GLS*S paving the way for breast cancer.

GLSI has announced the abstract results of the final 5-year immune response data of the Phase 2b trial at the 2021 AACR Annual Meeting.
The company plans to publish the poster, the abstract, and an audio recording tomorrow in a joint press release.
Potent immune response data, supports the previously reported clinical outcome of 0% metastatic breast cancer recurrences over five years of follow-up.
A statistically significant peak immunity was reached after six months of GP2 treatment as measured in both a GP2 specific CD8 T cell dimer binding assay and a delayed-type-hypersensitivity (DTH) skin test.
HER2 3+ population immune response was similar to the HER2 1-2+ population immune response, suggesting the potential to treat the HER2 1-2+ population with GP2 immunotherapy in combination with trastuzumab (Herceptin) based products and other clinically active agents.
GP2 is immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.

https://www.abstractsonline.com/pp8/#!/9325/presentation/5254

tomorrow she runs,, abstract posted for GLSI

Interesting read here.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163047099

Great move lol

It might be resurrected...Who knows?

Looking good

Is today the day we break $40 PPS and sustain ?

5 year 0% reoccurrence for breast cancer. Greenwich LifeSciences. This is remarkable and what the whole world has been waiting for. $100 PPS near term?

Only 12mill share OS!! https://www.otcmarkets.com/stock/GLSI/security

Agree. Was this little pop today a sign ?

Agree this is a take over candidate !! Whatever ran this $100 plus recently can do it again ?

Pfizer will be according to our desks

It was nuts. This Is a great trading stock to build your core position. Lot of potential here but not much for near term catalyst unless they partner.

What the heck GLSI ?!!!
I was tired of this sitting, and expecting a pull back market wide so sold 750 shares at 2:08pm today 1/7 for $34.82 at $1.10 loss per share...
I blink my eye & within 40 minutes its over $42 ? !!!

Can we see $100 plus again in the near future?

Pfizer is my guess- 5 year 0% reoccurrence for breast cancer. Greenwich LifeSciences. This is remarkable and what the whole world has been waiting for. Will continue to add all the way, I see at the very least $150-$200 ahead which is still a fraction of market share who ever will buy them to capitalize on. We’re talking a 10-15+ Billion dollar space and unmet demand here.
2021 will be a prosperous year for all holders here

I am a complete idiot for falling for that one. What a joke. What a scam. Pump and Dump. The SEC doesn’t exist. If they did, this shit wouldn’t fly. Classic pump scheme.

The stock was 3.28 that morning. You paid 100. This market is doomed I e been saying it for months.

Does anyone know was there a recent R/S on this stock?

$75-$100- patience- this will be huge and what a market space they’ll capitalize

Take a look at HGEN.. I m late to the party here but bought in at $38

I would like to have a little fun today. Best case scenario, what is the possible cash per share value of Anavex with multiple SOC indications?

I agree.

Add what you can here and take advantage. Float is micro low and now they are funded to moved ahead with approx 27 million cash. If tutes are willing to pay $43-$44, one can only imagine how easily they spike this up when they’re ready. We’re talking 5-7 BILLION market share this company’s drug will be able to capture ahead
Add all you can $40-$50 levels and wait for $80-$100 down road
$GLSI

Man.. gotta imagine those in at the low cashed in big time then shorted this thing back down for a double dip.

Crazy

Ok so what is the general consensus on where this stock is going moving forward?

I feel your pain.

Got stuck in the halt drama.

Got 100 at $100

Can’t believe I fell for this POS.

10 grand goodbye. FML.

* * $GLSI Video Chart 12-11-2020 * *

Link to Video - click here to watch the technical chart video

Looks like the big boys cashed their tickets and are tanking her back down to single digits

Hopefully it bounces back

Going to be a Green Day here MARK IT $$$$

Not looking good today again for the peeps that bought high.

* * $GLSI Video Chart 12-10-2020 * *

Link to Video - click here to watch the technical chart video

It could bounce back up in the afternoon, IMO.